Free Trial
→ Read now. Do not delete. You’ve been warned. (From Porter & Company) (Ad)tc pixel
NASDAQ:IBIO

iBio Q2 2026 Earnings Report

iBio logo
$1.94 +0.10 (+5.16%)
As of 12:05 PM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

iBio EPS Results

Actual EPS
-$0.09
Consensus EPS
-$0.08
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A

iBio Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.10 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

iBio Announcement Details

Quarter
Q2 2026
Date
2/10/2026
Time
After Market Closes
Conference Call Date
Tuesday, February 10, 2026
Conference Call Time
4:00PM ET

Conference Call Resources

Powered by Quartr

Earnings Documents

iBio's Q2 2026 Press ReleasePress Release
(8-K)
iBio's Q2 2026 Quarterly reportQuarterly report
(10-Q)

iBio Earnings Headlines

iBio to Participate in Upcoming Healthcare Investor Conferences
June 2 at 4:01 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/02/3305569/0/en/ibio-to-participate-in-upcoming-healthcare-investor-conferences.html
iBio, Inc.: iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity
June 2 at 8:17 AM  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-06/68657523-ibio-inc-ibio-becomes-a-clinical-stage-company-with-first-participant-dosed-in-phase-1-clinical-trial-of-ibio-600-in-adults-with-obesity-399.htm
Stranded On The Flood Plains of History
The petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed U.S. Treasury holdings by 45% from peak, and central banks are swapping dollars for gold at the fastest pace since the Cold War. Porter Stansberry believes Trump is channeling more than $3 trillion toward securing the minerals, chips, and infrastructure that make AI possible - and companies at those chokepoints like Vertiv (up 500%), GE Vernova (up 700%), and Arista Networks (up 750%) are already moving. Porter's new briefing names one asset to buy today plus five stocks positioned at the narrowest chokepoints of what he calls the Silicon Dollar.tc pixel
June 4 at 1:00 AM  |  Porter & Company (Ad)
iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity
June 2 at 7:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/02/3304990/0/en/ibio-becomes-a-clinical-stage-company-with-first-participant-dosed-in-phase-1-clinical-trial-of-ibio-600-in-adults-with-obesity.html
iBio (NASDAQ:IBIO) Stock Rating Upgraded by Wall Street Zen
May 30, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30808386
iBio, Inc. (NASDAQ:IBIO) Receives Average Recommendation of "Buy" from Analysts
May 26, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30801130
See More iBio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like iBio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on iBio and other key companies, straight to your email.

About iBio

iBio (NASDAQ:IBIO), a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.

View iBio Profile
Earnings Tools